It has been widely reported regarding relationship between depression and cognitive function. Benzodiazepines (BZD) has been reported that there is risk by which it itself has an influence on the cognitive function. The aim of the present study was to clarify whether BZD influenced to the cognitive impairment in remitted depression.
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Factors associated with relapse after a response to electroconvulsive therapy in unipolar versus bipolar depression Kei Itagake, Hiromi Abe, Yousuke Fujita, Naoato Kajitani, Kenichi Oga, Mami Okada-Tsuchioka, Wataru Omori, Chiyo Shibasaki, Minoru Takebayashi National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Japan Abstract Background: Despite the effectiveness of electroconvulsive therapy (ECT) treatment for depression, there is a high rate of relapse, even with maintenance pharmacotherapy. This study investigated factors associated with a risk of relapse in mood disorders after a response to ECT. Method: The records of 78 patients with mood disorders (46 unipolar depression, 32 bipolar depression) who received and responded to an acute ECT course were retrospectively reviewed. Patients with records for at least one year were included. An association between clinical variables and relapse after a response to acute ECT was analyzed. Relapse was defined as a Clinical Global Impressions Improvement score ≥6 or a psychiatric rehospitalization. Results: After one year, the relapse-free rate of all patients at one year was 44.9% and there were no significant difference between patients with either unipolar or bipolar depression who were relapse-free (unipolar: 45.7%, bipolar: 43.7% P = 0.868). The mean duration until relapse was 21.6 ± 11.2 months (unipolar: 22.0 ± 11.6 months, bipolar: 20.9 ± 10.8 months, P = 0.796). Maintenance pharmacotherapy with valproate in patients with unipolar depression was associated with a lower risk of relapse compared to patients without valproate treatment (multivariate analysis, hazard ratio: 0.080; P = 0.025). Lithium treatment was associated with a tendency for a lower risk of relapse (hazard ratio: 0.413; P = 0.091). Female sex was associated with a tendency for an increased risk of relapse (hazard ratio: 2.517; P = 0.089). For bipolar depression, quetiapine treatment tended to lower the risk of relapse (hazard ratio: 0.144; P = 0.081). Limitation: The current findings were based on a limited sample size and retrospective. Conclusions: Although the relapse-free rate was similar between unipolar and bipolar depression, effective maintenance pharmacotherapy differed. In unipolar depression, valproate could be effective in preventing relapse after an ECT.
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Altered serum levels of matrix metalloproteinase-2, -9 in response to electroconvulsive therapy for mood disorders. Abstract Background: Mood disorders are being increasingly recognized as having a strong association with chronic inflammatory states. Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMP) are inflammation-related molecules. The major MMPs, MMP-2, -9, and TIMP-2, -1, are inflammatoryrelated molecules that likely have key roles in mood disorders. The current study sought an association between mood disorders and systemic levels of MMPs and TIMPs. Methods: Serum was obtained from patients with mood disorders (MD) (N = 21) and patients with schizophrenia (SCZ) (N = 13) scheduled to undergo electroconvulsive therapy (ECT). Serum was also obtained from healthy controls (N = 40). Clinical symptoms were assessed by the Hamilton Rating Score for Depression and the Brief Psychiatric Rating Scale. Serum levels of MMPs and TIMPs were quantified by enzyme-linked immunosorbent assay. Results: The serum levels of MMP-2 in MD patients, but not in SCZ patients, prior to the first ECT session (baseline), were significantly lower than those of healthy controls. At baseline, levels of MMP-9 and TIMP-2, -1 were not different between patients with MD, SCZ and healthy controls. After a course of ECT, MMP-2 levels were significantly increased in MD patients but MMP-9 levels significantly decreased in both MD and SCZ patients. In MD patients, there was a significant negative correlation between depressive symptoms and serum levels of MMP-2 and a positive correlation between depressive symptoms and MMP-9. In addition, alterations of serum levels of MMP-2 and 9 were significantly correlated each other and were associated with certain depressive symptoms. Conclusion: A change in inflammatory homeostasis, as indicated by MMP-2 and MMP-9, could be related to mood disorders and these markers appear to be sensitive to ECT.
